CN108712908A - 自交联抗体 - Google Patents

自交联抗体 Download PDF

Info

Publication number
CN108712908A
CN108712908A CN201780016120.2A CN201780016120A CN108712908A CN 108712908 A CN108712908 A CN 108712908A CN 201780016120 A CN201780016120 A CN 201780016120A CN 108712908 A CN108712908 A CN 108712908A
Authority
CN
China
Prior art keywords
meditope
antigen
antibody
enabled
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780016120.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·杜米特鲁
伊丽莎白·M·加迪纳
罗伯特·P·麦肯锡
M·H·马托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meditope Biosciences Inc
Original Assignee
Meditope Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meditope Biosciences Inc filed Critical Meditope Biosciences Inc
Publication of CN108712908A publication Critical patent/CN108712908A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201780016120.2A 2016-01-08 2017-01-09 自交联抗体 Pending CN108712908A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276803P 2016-01-08 2016-01-08
US62/276,803 2016-01-08
US201662317342P 2016-04-01 2016-04-01
US62/317,342 2016-04-01
PCT/US2017/012754 WO2017120599A1 (en) 2016-01-08 2017-01-09 Self-crosslinking antibodies

Publications (1)

Publication Number Publication Date
CN108712908A true CN108712908A (zh) 2018-10-26

Family

ID=59274084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780016120.2A Pending CN108712908A (zh) 2016-01-08 2017-01-09 自交联抗体

Country Status (8)

Country Link
US (1) US11459397B2 (https=)
EP (1) EP3399992A4 (https=)
JP (1) JP6983808B2 (https=)
KR (1) KR20180098672A (https=)
CN (1) CN108712908A (https=)
AU (1) AU2017205343A1 (https=)
CA (1) CA3010632A1 (https=)
WO (1) WO2017120599A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884128A (zh) * 2016-02-02 2018-11-23 梅迪托普生物科学有限公司 抗egfr抗体药物缀合物
CN109521192A (zh) * 2018-11-27 2019-03-26 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
CN112661828A (zh) * 2021-01-15 2021-04-16 武汉大学 一种突触素的抗原肽及其抗体与应用
WO2022068141A1 (zh) * 2020-09-29 2022-04-07 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
CN115677856A (zh) * 2021-07-29 2023-02-03 东莞市朋志生物科技有限公司 抗人IgM抗体及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112088169A (zh) * 2018-03-12 2020-12-15 纪念斯隆凯特琳癌症中心 双特异性结合剂及其用途
AU2020361622A1 (en) * 2019-10-10 2022-04-28 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic viruses that express multi-specific immune cell engagers
JP7848114B2 (ja) * 2019-10-12 2026-04-20 バイオ－セラ ソリューションズ リミテッド 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用
EP4071178A4 (en) * 2019-12-06 2024-10-09 Ajinomoto Co., Inc. METHOD FOR PREPARING A PEPTIDE WITH PHYSIOLOGICAL ACTIVITY AND A PEPTIDE WITH A SHORT LINKER
JPWO2022158554A1 (https=) * 2021-01-22 2022-07-28
CA3212386A1 (en) * 2021-03-18 2022-09-22 Alessandro ARCOVITO Ferritin variants with increased stability and complexation ability
JP2024025400A (ja) * 2022-08-12 2024-02-26 浜松ホトニクス株式会社 膜貫通タンパク質を標的オルガネラに局在化させるためのペプチドリンカー及び局在化方法並びに局在化する融合タンパク質

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221477A1 (en) * 2004-07-26 2009-09-03 Asterion Limited Linkers
WO2012048332A2 (en) * 2010-10-08 2012-04-12 John Williams A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2013055404A1 (en) * 2011-10-10 2013-04-18 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US9428553B2 (en) * 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP3200823B1 (en) * 2014-10-02 2022-11-23 City of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
EP3842448A1 (en) * 2015-05-15 2021-06-30 City of Hope Chimeric antigen receptor compositions
KR20180105227A (ko) * 2016-02-02 2018-09-27 메디토페 바이오사이언시스, 아이엔씨. 항-egfr 항체 약물 접합체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221477A1 (en) * 2004-07-26 2009-09-03 Asterion Limited Linkers
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
WO2012048332A2 (en) * 2010-10-08 2012-04-12 John Williams A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2013055404A1 (en) * 2011-10-10 2013-04-18 City Of Hope Meditopes and meditope-binding antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSHUA M DONALDSON 等: "Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies", 《PROC NATL ACAD SCI U S A》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884128A (zh) * 2016-02-02 2018-11-23 梅迪托普生物科学有限公司 抗egfr抗体药物缀合物
CN109521192A (zh) * 2018-11-27 2019-03-26 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
CN109521192B (zh) * 2018-11-27 2021-07-13 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
WO2022068141A1 (zh) * 2020-09-29 2022-04-07 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
CN114316063A (zh) * 2020-09-29 2022-04-12 昆明赛诺制药股份有限公司 抗-cd22抗体分子或其抗原结合片段及其应用
CN115210262A (zh) * 2020-09-29 2022-10-18 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
CN114316063B (zh) * 2020-09-29 2023-12-26 昆明赛诺制药股份有限公司 抗-cd22抗体分子或其抗原结合片段及其应用
CN112661828A (zh) * 2021-01-15 2021-04-16 武汉大学 一种突触素的抗原肽及其抗体与应用
CN115677856A (zh) * 2021-07-29 2023-02-03 东莞市朋志生物科技有限公司 抗人IgM抗体及其应用
CN115677856B (zh) * 2021-07-29 2023-11-28 东莞市朋志生物科技有限公司 抗人IgM抗体及其应用

Also Published As

Publication number Publication date
EP3399992A1 (en) 2018-11-14
US20190016822A1 (en) 2019-01-17
WO2017120599A1 (en) 2017-07-13
EP3399992A4 (en) 2019-07-31
JP6983808B2 (ja) 2021-12-17
JP2019509054A (ja) 2019-04-04
CA3010632A1 (en) 2017-07-13
AU2017205343A1 (en) 2018-07-19
KR20180098672A (ko) 2018-09-04
US11459397B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
AU2020289727B2 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
CN112512581B (zh) 针对cldn18.2和cd3的抗体构建体
TWI901940B (zh) 介白素-21突變蛋白及治療方法
CN108712908A (zh) 自交联抗体
CN113301919B (zh) 激活免疫细胞的双特异性抗体
ES2780948T3 (es) Proteínas de fusión de inmunoglobulinas en hélice enrollada y composiciones de las mismas
CN113056486B (zh) 改善的抗flt3抗原结合蛋白
US11254745B1 (en) Anti-CD4 antibodies
US20250188166A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
JP2026508244A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
CN111253486B (zh) 抗pd-1抗体及其用途
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
RU2830982C2 (ru) Улучшенные анти-flt3 антигенсвязывающие белки
HK1242589A1 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
HK1242589B (en) Multivalent meditopes, meditope-binding antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181026

WD01 Invention patent application deemed withdrawn after publication